甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Parathyroid Hormone Related Protein (PTHrP) ,etc. by FLIA (Flow Luminescence Immunoassay)
PTHLH; HHM; PTHR; PLP; Osteostatin; Parathyroid Hormone Like Hormone
（注：單次混測多因子不超過8個指標(biāo) ）
- 編號ULMA819Bo
- 物種Bos taurus; Bovine (Cattle，牛) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.98-1000pg/mL
- 靈敏度最小可檢測劑量小于等于0.327 pg/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價格 ¥ 1415 ¥ 1469 ¥ 1551 ¥ 1660 ¥ 1769 ¥ 1932 ¥ 2177 ¥ 2721 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 78-93 | 86 |
| EDTA plasma(n=5) | 78-88 | 82 |
| heparin plasma(n=5) | 91-105 | 102 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 98-105% | 80-103% | 89-97% | 83-90% |
| EDTA plasma(n=5) | 80-95% | 85-104% | 79-94% | 80-101% |
| heparin plasma(n=5) | 83-96% | 83-101% | 91-99% | 81-98% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Bos taurus; Bovine (Cattle，牛) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA819Bo01 | 甲狀旁腺激素相關(guān)蛋白(PTHrP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA819Bo01 | 甲狀旁腺激素相關(guān)蛋白(PTHrP)多克隆抗體 | WB |
| UMAA819Bo21 | 甲狀旁腺激素相關(guān)蛋白(PTHrP)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA819Bo | 甲狀旁腺激素相關(guān)蛋白(PTHrP)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA819Bo | 甲狀旁腺激素相關(guān)蛋白(PTHrP)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Clinical and Experimental Metastasis | Characterization of a new renal cell carcinoma bone metastasis mouse model [PubMed: 20443133] |
| Stem Cells and Development | Temporal activation of β-catenin signaling in the chondrogenic process of mesenchymal stem cells affects the phenotype of the cartilage generated. [PubMed: 22133004] |
| International journal of biological sciences | PTHrP Expression in Human MDA-MB-231 Breast Cancer Cells Is Critical for Tumor Growth and Survival and Osteoblast Inhibition [PubMed: PMC3753447] |
| Investigational New Drugs | Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts [Pubmed: 23673814] |
| Toxicology and Applied Pharmacology | Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment [Pubmed:24463094] |
| Arch Gynecol Obstet. | Calcitonin gene-and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case–control study [Pubmed:24943060] |
| PLoS One | 15-Deoxy-Δ12, 14-Prostaglandin J2 Inhibits Osteolytic Breast Cancer Bone Metastasis and Estrogen Deficiency-Induced Bone Loss [PubMed: 25859665] |
| Endocrinology | A role for the calcitonin receptor to limit bone loss during lactation in female mice by inhibiting osteocytic osteolysis [PubMed: 26135836] |
| Tumour Biol | Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation. [Pubmed:27312487] |
| 35 | Hedgehog signaling in bone regulates whole-body energy metabolism through a bone–adipose endocrine relay mediated by PTHrP and adiponectin [pubmed:27740628] |
| Bone | Lactation induces increases in the RANK/RANKL/OPG system in maxillary bone [Pubmed:29382610] |
| International Journal of Molecular Sciences | A Diet Rich in Fish Oil and Leucine Ameliorates Hypercalcemia in Tumour-Induced Cachectic Mice [Pubmed: 31600911] |
| Journal of Orthopaedic Surgery and Research | Identification of a potential gene target for osteoarthritis based on bioinformatics analyses [Pubmed: 32571421] |
| International Immunopharmacology | Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related?… [] |
| Паратиреоидный гормон-родственный протеин как предиктор развития мочекаменной болезни [] | |
| Cell Death Dis | Extracellular vesicles-released parathyroid hormone-related protein from Lewis lung carcinoma induces lipolysis and adipose tissue browning in cancer ?- [33510128] |
| Sci Rep | Effects of whole-body vibration training in a cachectic C26 mouse model [34732809] |
| Acta Physiologica | The acute adaptation of renal phosphate transporters in the murine kidney to oral phosphate intake requires multiple signals [Pubmed:35334154] |
